GSK, On Sunday, Announced First Global Phase Ib EMBOLD PanTumour-101 Data Showing Anti-Tumour Activity, Manageable Safety Profile For Ris-Rez In Relapsed ES-SCLC

Loading news article.

GSK, On Sunday, Announced First Global Phase Ib EMBOLD PanTumour-101 Data Showing Anti-Tumour Activity, Manageable Safety Profile For Ris-Rez In Relapsed ES-SCLC | WAPE

GSK, On Sunday, Announced First Global Phase Ib EMBOLD PanTumour-101 Data Showing Anti-Tumour Activity, Manageable Safety Profile For Ris-Rez In Relapsed ES-SCLC

Article summary

Related companies

Comments —